We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Argenta Announces Record Year for Peer-Reviewed Publications
News

Argenta Announces Record Year for Peer-Reviewed Publications

Argenta Announces Record Year for Peer-Reviewed Publications
News

Argenta Announces Record Year for Peer-Reviewed Publications

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Announces Record Year for Peer-Reviewed Publications"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Argenta has announced that 2013 has seen a record number of peer-reviewed publications featuring its scientists as co-authors with its clients and collaborators. The 2013 total of 15 publications surpasses the previous record of 13 achieved in 2007.

The publications have been co-authored with clients such as Genentech, AstraZeneca and Corcept and include papers in such prestigious journals as Nature and Proceedings of the National Academy of the USA.

Details of these, and other Argenta publications, can be found on the company’s website: http://www.argentadiscovery.com/news/publications.htm.

Dr John Montana, Managing Director of Argenta, commented, “Argenta stands or falls by the quality of the science that it conducts for and together with its clients. This record number of publications in high-quality, peer-reviewed scientific journals is another indication of the scientific prowess of Argenta’s industry-experienced staff and the success that we have achieved in partnership with our clients”.

A further indication of Argenta’s strength in drug discovery is the 40 development compounds that it has delivered on behalf of its clients during the 13 years since its inception.

The clinical progress of some of these can be seen on the company’s website: http://www.argentadiscovery.com/about/candidate-compound-progression.htm.

Advertisement